仁度生物1月22日获融资买入114.64万元，融资余额3394.72万元

Group 1 - The core viewpoint of the news is that Rendu Biotech has shown mixed financial performance, with a decrease in revenue but an increase in net profit, indicating potential resilience in profitability despite revenue challenges [2] - As of January 22, Rendu Biotech's stock price increased by 0.38%, with a trading volume of 18.35 million yuan, and a net financing outflow of 864,000 yuan, suggesting a cautious investor sentiment [1] - The company's financing balance reached 33.95 million yuan, accounting for 1.60% of its market capitalization, which is above the 90th percentile of the past year, indicating a high level of leverage [1] Group 2 - Rendu Biotech's main business revenue composition includes 90.04% from reagent business, 8.49% from instrument business, and 1.47% from testing services, highlighting its focus on molecular diagnostic products [1] - As of September 30, the number of shareholders increased by 7.73% to 3,765, with an average of 10,642 circulating shares per person, indicating growing investor interest [2] - For the period from January to September 2025, Rendu Biotech reported a revenue of 119 million yuan, a year-on-year decrease of 8.79%, while the net profit attributable to shareholders increased by 50.15% to 7.01 million yuan, reflecting improved profitability [2]